Evidence map›Paper›PMID 27471394›Full record

ArticleOncoTargets and therapy2016

Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer.

Xiao-Ming Xu, Cheng-Gong Wang, Yu-Di Zhu, Wei-Hua Chen, Si-Liang Shao, Fu-Neng Jiang, Qian-De Liao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Reduction in the hepatocellular carcinoma antioncogeneWorld journal of gastrointestinal surgery · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Chromosomal assembly of the flat oyster (Evolutionary applications · 2022
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Xiao-Ming XuXiangya Hospital, Central South University, Changsha, Hunan; Department of Urology, Ningbo No 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang.
Cheng-Gong WangXiangya Hospital, Central South University, Changsha, Hunan.
Yu-Di ZhuDepartment of Urology, Ningbo No 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang.
Wei-Hua ChenShanghai East Hospital, Tongji University, Shanghai.
Si-Liang ShaoDepartment of Urology, Ningbo No 2 Hospital, Ningbo University School of Medicine, Ningbo, Zhejiang.
Fu-Neng JiangGuangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, People's Republic of China.
Qian-De LiaoXiangya Hospital, Central South University, Changsha, Hunan.
Xiangya Hospital Central South University · CNCentral South University · CNGuangzhou Medical University · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSolute carrier family 39, member 14 (SLC39A14), has been identified as a potential biomarker for various cancers. However, its roles in prostate cancer (PCa) are still unclear. The aim of this study was to investigate the clinical significance of SLC39A14 in patients with PCa and its functions in malignant phenotypes of PCa cells. PATIENTS AND

methodsSubcellular localization and expression pattern of SLC39A14 protein were examined by immunohistochemistry. Then, the associations of SLC39A14 expression with various clinicopathological features and clinical outcome of patients with PCa were statistically evaluated. Subsequently, the effects of SLC39A14 overexpression and knockdown on PCa cell proliferation and motility were, respectively, examined by Cell Counting Kit-8, transwell, and wound-healing assays.

resultsThe immunoreactive scores of SLC39A14 protein in human PCa tissues were significantly lower than those in normal prostate tissues. Based on the Taylor dataset, SLC39A14 downregulation occurred more frequently in patients with PCa with a higher Gleason score (P<0.001), advanced clinical stage (P=0.008), presence of metastasis (P=0.009), and prostate-specific antigen failure (P=0.006). More interestingly, the survival analysis identified SLC39A14 as an independent factor for predicting the biochemical recurrence-free survival of patients with PCa (P=0.017). Functionally, the enforced expression of SLC39A14 could suppress cell proliferation, invasion, and migration of PCa cell lines in vitro, which could be reversed by the knockdown of SLC39A14.

conclusionDecreased expression of SLC39A14 may lead to malignant phenotypes of PCa cells and aggressive tumor progression in patients with PCa. Importantly, SLC39A14 may function as a tumor suppressor and a biomarker for screening patients with biochemical recurrence following radical prostatectomy.

Indexed as

biochemical recurrence-free survivalprostate cancersolute carrier family 39 member 14tumor suppressor

Identifiers

PMID27471394
PMCPMC4948725
OpenAlexW2466491482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.